After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities
This article was originally published in PharmAsia News
For almost the entire month of March, Eli Lilly & Co. CEO John Lechleiter ran his company from China, a feat that included hosting Lilly's annual global leadership summit in Shanghai, where 150 high-level Lilly execs gathered to get a firsthand look at the country, visiting hospitals and research centers and meeting with government officials
You may also be interested in...
China’s SFDA recently released its third annual drug registration report. The agency approved 718 drugs and APIs in 2011, including five NCEs.
Following Eli Lilly’s launch of Forteo in China last November, Merck is launching FosaMax Plus, a vitamin D compounded version of its osteoporosis blockbuster FosaMax.
In this periodic feature, PharmAsia News listens in at major industry events to what senior executives have to say about Asia and other emerging markets. For this profile, we zoom in on the Sanford Bernstein Strategic Decisions Conference, held June 1-2 in New York City.